N
News Analysis
tickerreport.com

www.tickerreport.com ·

Positive

ptc therapeutics nasdaqptct vp mark elliott boulding sells 3540 shares of stock

TAX_FNCACT_INSIDEREPU_CATS_REGULATIONEPU_CATS_FINANCIAL_REGULATIONKILL

All NewsRead the full story on tickerreport.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

Insider stock sale by a VP of PTC Therapeutics, a biotech company. No direct commercial mechanism for any sector; the transaction is routine and does not indicate a change in company fundamentals or market conditions. No product, supply chain, or scarcity impact.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • Mark Elliott Boulding, VP of PTC Therapeutics, sold 3,540 shares on May 8, 2026 at $78.97, totaling $279,553.80.
  • Following the sale, Boulding holds 105,212 shares valued at ~$8.31 million, a 3.26% decrease.
  • PTC Therapeutics reported Q1 2026 revenue of $272.55 million, exceeding estimates.
  • Market cap of PTC Therapeutics is $6.22 billion.

About the publisher

tickerreport.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

Coverage of incidents involving fatalities. Numbers and causes are taken from primary reporting.

ptc therapeutics nasdaqptct vp mark elliott boulding sells 3540 shares of stock | tickerreport.com — News Analysis